Posts

Merck’s Lipfendra becomes world’s first oral PCSK9 treatment approved by FDA

on

Lilly reports new Phase 1b data on PCSK9 base‑editing gene therapy from Verve buyout

on

Merck Unveils Phase 3 Data: Oral PCSK9 Inhibitor Enlicitide Outperforms Rivals in Cholesterol Reduction

on

Merck Touts Strong Comparator Data for Enlicitide Decanoate, Oral PCSK9 Inhibitor Reducing LDL-C by Up to 60% in Phase 3 Trials

on

Merck Reports Pivotal PCSK9 Pill Data in Race to Beat AstraZeneca to Market

on

Amgen Builds Case for Repatha to Prevent Heart Disease With Landmark Late-Stage Data

on

Merck's Oral PCSK9 Inhibitor Enlicitide Significantly Reduces LDL Cholesterol in Phase 3 Trials

on

NewAmsterdam's pooled Phase 3 data; C4 seeks partners for solid tumor degrader

on

Solbinsiran Demonstrates Significant Lipid Reductions in Phase 2 Trial for Mixed Dyslipidemia

on